Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells in Severe Ocular Chemical Burn

Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells in Severe Ocular Chemical Burn SyMbOL Pre Clinical Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03967275

Acronym

SYMBOLpreclini

Enrollment

Registered

2019-05-30

Start date

2020-09-09

Completion date

2022-06-01

Last updated

2022-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Marrow Donor

Keywords

Bone marrow harvest, Bone Marrow derived Mesenchymal Stem Cells (BM-MSC), Pre-clinical

Brief summary

The objective of this pre-clinical study is to demonstrate the robustness of Bone Marrow derived Mesenchymal Stem Cells (BM-MSC) production, to treat patients with severe eye burns. For bone marrow donors who agree to participate, a 10 ml BM sample will be collected apart the 1 liter BM dedicated to transplantation. A maximum of three donors of allogeneic BM-MSCs will be included. A ready-to-use BM-MSC suspension will be produced and stored for 10 years to accumulate data about stability of cryopreserved cells.

Interventions

OTHERbone marrow harvest

During bone marrow harvest, an additional 10 mL sample will be collected for the study.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

\- Patient with a bone marrow donation planned

Exclusion criteria

* The donor is finally not eligible * The harvest cannot be performed * The sample cannot be obtained during the BM harvest procedure

Design outcomes

Primary

Measure	Time frame
The number of donors needed to obtain 3 BM harvest.	6 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026